UBS Starts Diplomat Pharmacy (DPLO) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/17/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Micron Technology stock drops on China chip news and labor dispute
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
Mizuho Securities Cuts Price Target as Recent Sell-offs of Specialty Pharma Manufactures Negatively Effect Diplomat Pharmacy (DPLO)
October 21, 2015 6:43 AM EDTMizuho Securities maintained a Buy rating on Diplomat Pharmacy (NYSE: DPLO), and cut the price target to $44.00 (from $53.00), following recent sell-offs of specialty pharmacy manufactures. DPLO does not distribute any VRX or HZNP products. DPLO manages and distributes complex drugs for chronic conditions unlike... More



